Halozyme price target raised to $95 from $90 at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Halozyme (HALO) to $95 from $90 and keeps a Buy rating on the shares. A Q1 royalty reset is expected, and H.C. Wainwright is looking for signs that Halozyme’s royalty momentum re-accelerates into Q2 and subsequent quarters in 2026, the analyst tells investors in a research note.